Liz Morrell
MA MSc PhD FHEA
Senior Researcher
Liz joined Health Economics Research Centre (HERC) in February 2018, from the Centre for the Advancement of Sustainable Medical Innovation (CASMI) - a policy research group in Oxford’s Radcliffe Department of Medicine.
She is working with Sarah Wordsworth and colleagues, initially on a series of Discrete Choice Experiments exploring clinician and public attitudes to antibiotics and antimicrobial resistance.
Her work focused on the health economics of cancer drugs, exploring the impact of technology appraisal processes on patient access to drugs, and the value that society places on treating cancer relative to other conditions.
Before joining CASMI, Liz worked as a freelance researcher with clients in pharmaceuticals and education, and as a product development manager in consumer healthcare.
Recent publications
Is liquid biopsy a cost-effective method to diagnose Burkitt Lymphoma in children and young adults? A health economic evaluation in Tanzania.
Journal article
Jiang J. et al, (2026), BMC Med
Optimising antibiotic “review and revise” in acute/general medical inpatients: the Antibiotic Review Kit in Hospitals (ARK-Hospital) research programme including a stepped-wedge cluster-randomised trial
Journal article
Llewelyn MJ. et al, (2025), NIHR Journals Library
Diagnosing Burkitt Lymphoma in Sub-Saharan Africa by Sequencing of Circulating Tumor DNA: A Comparative Microcosting Study.
Journal article
Morrell L. et al, (2025), Value Health Reg Issues, 48
Rituximab for children with EBV-positive Burkitt lymphoma in East Africa.
Journal article
Mawalla WF. et al, (2025), Blood Adv, 9, 2393 - 2401
Targeted Next-Generation Sequencing of Cell-Free DNA to Detect MYC-Immunoglobulin Translocation and Epstein-Barr Virus DNA in Plasma of Burkitt Lymphoma Patients in East Africa.
Journal article
Chamba C. et al, (2025), JCO Glob Oncol, 11
